MedTrace Logo

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

NCT03137888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-03

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyond current clinical MRI scans by mapping areas of high tumor metabolism. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Spectroscopic MRI-guided radiation therapy may work better in treating patients with glioblastoma or gliosarcoma.

Conditions

Interventions

RADIATION

Dose-Escalated Radiation Therapy

Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks

PROCEDURE

Spectroscopic Magnetic Resonance Imaging

Patients will undergo sMRI scans within a 14 day window prior to starting treatment

DRUG

Temozolomide

Given PO

Sponsors & Collaborators

  • Johns Hopkins University

    collaborator OTHER

  • University of Miami

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Hui-Kuo Shu, MD, PhD · Emory University/Winship Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2024-09-09
Completion
2024-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03137888 on ClinicalTrials.gov